Identification:
a. Symptoms: Sudden onset of fever, headache, nausea, vomiting, lethargy, and irritability in cases of meningococcemia; headache, nausea, vomiting, and stiff neck in cases of meningitis. A petechial rash is seen frequently. Delirium and coma are not uncommon. Fulminant cases may present with ecchymosis and shock.
b. Differential Diagnosis: Other bacterial or viral agents of meningitis and sepsis, rickettsial diseases (e.g., Rocky Mountain spotted fever), and anaphylactoid purpura.
c. Diagnosis: Positive culture or detection of N. meningitidis-specific nucleic acid from a normally sterile site, e.g., blood or cerebrospinal fluid; positive bacterial antigen test in CSF or gram-negative diplococci in a normally sterile site. A clinical diagnosis or clinically compatible presentation, specifically clinical purpura fulminans, in the absence of laboratory confirmation, must be investigated.
3. Incubation: 2-10 days; commonly 3-4 days. h. Recent out-of-county travel.
i. Gender of sexual partners (i.e., is patient a man who has sex with men (MSM)).
j. Meningococcal vaccination history.
k. HIV status.
l. Student or staff at a school.
CONTROL OF CASE, CONTACTS & CARRIERS
1. Investigate the day of report.
2. During business hours, ACDC to directly notify CS Public Health Nursing Supervisor (PHNS) and copy Area Medical Director (AMD).
3. After hours, AOD to complete After Hours Worksheet and, if applicable, directly notify CS AOD.
Public Health Nursing Protocol:
Home visit is required -a face to face interview is required.
Refer to "Public Health Nursing Home Visit Required Algorithm" (B-73 Part IV Public Health Nursing Home Visit Protocol 4 ).
CASE:
Droplet precautions in addition to standard precautions until 24 hours after start of antibiotic therapy. 4. Contact school or daycare center to provide education and notification of exposure, as well as to conduct surveillance.
5. Discontinue surveillance after 10 days.
6. Surveillance of carriers requires individual evaluation. Routine culturing of nasopharynx is not indicated.
OUTBREAKS
A meningococcal disease outbreak is defined by the occurrence of multiple confirmed or probable primary cases of meningococcal disease of the same serogroup in a community or institution over a short period of time. This may be as little as 2 cases depending on the size of the institution or circumstance.
The population at-risk is defined as a group of persons who, in addition to close contacts, are considered to be at increased risk for N. meningitidis when compared with the risk for this disease in the general U.S. population. This group is usually defined on the basis of organizational affiliation or community affiliation.
Meningococcal vaccines may be recommended for use in control of N. meningitidis outbreaks caused by vaccine preventable serogroups (see PREVENTION-EDUCATION section). • Travelers to countries in which N. meningitidis is hyper-endemic or epidemic, particularly if contact with the local population will be prolonged.
PREVENTION-EDUCATION
• Persons infected with HIV (require 2 dose primary series).
• Men who have sex with men, regardless of HIV status.
• Military recruits.
• Persons with anatomic or functional asplenia (require 2 dose primary series and booster doses every 5 years). Serogroup B vaccine also recommended.
• Persons with terminal complement deficiency including those taking Soliris® for treatment (require 2 dose primary series and booster doses every 5 years). Serogroup B vaccine also recommended.
• Research, industrial, and clinical laboratory workers who are routinely exposed to N. meningitidis in solutions 
DIAGNOSTIC PROCEDURES
Diagnosis of infection with N. meningitidis generally relies on evidence of the organism from blood or other normally sterile body sites. Refer to section, Identification: Diagnosis.
Molecular:
Culture-negative specimens from patients for whom there is a high clinical suspicion of meningococcal disease should be submitted for testing by polymerase chain reaction (PCR).
Material: 0.5 ml of EDTA-treated blood (purple top); and/or 0.5 ml of CSF. Send both blood and CSF, if available. 
Form

